Roivant Targets September 2026 Brepocitinib Launch Following Dermatomyositis Commercial Preparations

With a hard September 2026 launch window now confirmed, Roivant's Priovant subsidiary is compressing commercial timelines for brepocitinib in dermatomyositis into a narrow operational corridor that will test CMO batch release scheduling, GMP readiness, and supply chain coordination across specialty dermatology channels.

Roivant reported the launch preparations as on track in its Q1 fiscal 2026 results filed August 6, 2026. Brepocitinib, a TYK2/JAK1 inhibitor dosed at 45mg once daily, targets dermatomyositis, an orphan inflammatory myopathy with no previously approved therapy. For QA directors and plant heads supporting the program, the sub-60-day horizon to a potential commercial release means that process validation packages, batch disposition protocols, and any outstanding 21 CFR Part 211 documentation should already be in final review.

Beyond the DM launch, Roivant disclosed that the Phase 3 BEACON+ study in cutaneous sarcoidosis has enrolled its first patients. The trial targets approximately 140 patients across 70 global sites, randomized 3:2 between brepocitinib 45mg and placebo, with a primary endpoint of 50% or greater reduction in CSAMI-A score at Week 16. The Phase 2 BEACON trial posted a 77% response rate at that threshold versus 0% for placebo, supporting the FDA Breakthrough Therapy Designation that preceded this expansion. Topline data from BEACON+ are not expected until 2028, giving manufacturing and regulatory teams a longer runway for that indication.

Three additional readouts are expected before calendar year-end: topline data from the Phase 3 NIU study, the Phase 2 PH-ILD mosliciguat study, and the IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus. Each concurrent readout represents a potential regulatory submission trigger, and QA and regulatory affairs leads supporting multiple Roivant programs should anticipate overlapping CMC package demands in Q3 and Q4 2026.

On the financial side, Roivant reported consolidated cash, cash equivalents, restricted cash, and marketable securities of $3.9 billion as of June 30, 2026, excluding a $950 million payment received from Moderna in July 2026 under a $2.25 billion settlement with Genevant and Arbutus. An additional $1.3 billion remains contingent on the outcome of Moderna's Section 1498 appeal. New international litigation against Pfizer and BioNTech covering 21 jurisdictions was also filed.

The September 2026 brepocitinib launch date now functions as the near-term operational checkpoint against which CMO readiness, labeling finalization, and distribution network activation will be measured.

Source: Roivant Sciences via GlobeNewswire, August 6, 2026. Live conference call and webcast held at 8:00 a.m. ET on the same date.